Researchers used drug-conjugated nanopolymers combined with mass spectrometric analysis to precisely zero in on drug targets in vitro and in living cells. The method could allow for testing of new drug targets and prevent serious side effects that come from reaching unintended drug targets, according to the study published in Agnewandte Chemie International Edition.

Related Summaries